The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

10d ago, source:

Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average target is $17.5, ...

Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential

4d ago, source:

Analyst Colleen M. Kusy of Robert W. Baird reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the price ...

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

10d ago, source:

Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea ...

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

on MSN ago, source:

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy.

Ocular marks early-stage trial win for diabetic retinopathy candidate

on MSN ago, source:

Ocular Therapeutix (OCUL stock gained on positive Phase 1 results for its retinal disease candidate Axpaxli in diabetic ...

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

8d ago, source:

Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in ...

Baird sees weakness in Ocular shares as "overdone"

on MSN ago, source:

Baird said it thinks recent weakness in Ocular Therapeutix (OCUL) shares is "overdone" and remains bullish on the company’s ...

Ocular Therapeutix Inc (OCUL) Shares Down Despite Recent Market Volatility

3mon ago, source: newsheater

In summary, Ocular Therapeutix Inc (OCUL) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to ...

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

7d ago, source: ophthalmologytimes

According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity ...

Ocular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders

10d ago, source:

Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj ...

Ocular Therapeutix(TM) Announces Positive Topline Phase 1 Data for AXPAXLI(TM) in Diabetic Retinopathy

8d ago, source:

About AXPAXLI™ AXPAXLI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being ...